Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease brugada syndrome
Symptom C0042510|ventricular fibrillation
Sentences 22
PubMedID- 24761970 Time-domain t-wave alternans is strongly associated with a history of ventricular fibrillation in patients with brugada syndrome.
PubMedID- 20555410 Previous reports demonstrated that cilostazol, a phosphodiesterase 3 inhibitor, affected cellular electrophysiology and reduced episodes of ventricular fibrillation (vf) in patients with brugada syndrome.
PubMedID- 24616586 (2) also reported that normalization of a brugada pattern ecg in 89% after cfe-guide ablation in ventricular tachycardia/ventricular fibrillation (vt/vf) in patients with brugada syndrome and 78% long-term suppression of ventricular tachyarrhythmias.
PubMedID- 26171254 The use of an implantable cardiac defibrillator has been advocated as the only effective treatment for the management of ventricular fibrillation (vf) in patients with brugada syndrome (brs).
PubMedID- 25478533 Monomorphic ventricular tachycardia originating from right ventricular outflow tract as a trigger for the recurrent ventricular fibrillation in a patient with brugada syndrome.
PubMedID- 22622300 Suxamethonium and neostigmine were contraindicated to avoid the vagotonic effects that can precipitate ventricular fibrillation during anesthesia in patients with brugada syndrome.
PubMedID- 25989739 Utility of t-wave alternans during night time as a predictor for ventricular fibrillation in patients with brugada syndrome.
PubMedID- 20059716 High efficacy of disopyramide in the management of ventricular fibrillation storms in a patient with brugada syndrome.
PubMedID- 23131759 Current clinical and experimental data demonstrate that the electrocardiographic j wave plays a critical role in the pathogenesis of ventricular fibrillation (vf) in patients with brugada syndrome (bs) and early repolarization (er) syndrome (ers).
PubMedID- 20625312 Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with brugada syndrome with and without scn5a mutation.
PubMedID- 21200326 Recently, cilostazol has been shown to prevent ventricular fibrillation in patients with brugada syndrome.
PubMedID- 24703917 Objectives: this study aimed to determine the usefulness of the combination of several electrocardiographic markers on risk assessment of ventricular fibrillation (vf) in patients with brugada syndrome (brs).
PubMedID- 22123317 Identification of high-risk syncope related to ventricular fibrillation in patients with brugada syndrome.
PubMedID- 24931179 Epicardial ablation for prevention of ventricular fibrillation in a patient with brugada syndrome.
PubMedID- 21315838 Spontaneous electrocardiogram alterations predict ventricular fibrillation in brugada syndrome.
PubMedID- 21403098 Background: the underlying electrophysiological mechanism that causes an abnormal ecg pattern and ventricular tachycardia/ventricular fibrillation (vt/vf) in patients with the brugada syndrome (brs) remains unelucidated.
PubMedID- 22445599 Effects of isoproterenol and propranolol on the inducibility and frequency of ventricular fibrillation in patients with brugada syndrome.
PubMedID- 21075581 Isoproterenol has been used to terminate recurrent ventricular fibrillation in patients with brugada syndrome and torsades de pointes resistant to magnesium therapy.
PubMedID- 21048329 Scn5a mutation is associated with early and frequent recurrence of ventricular fibrillation in patients with brugada syndrome.
PubMedID- 26550443 Conclusion: in addition to ventricular tachycardia and ventricular fibrillation, patients with brugada syndrome exhibit various supraventricular tachyarrhythmia and third degree atrioventricular block.
PubMedID- 25240706 Near fatal ventricular fibrillation in brugada syndrome despite presence of an implanted implantable cardioverter defibrillator.
PubMedID- 24267814 We report the case of a very prolonged spontaneous episode of self-terminating ventricular fibrillation in a patient with brugada syndrome (brs).

Page: 1